Amendments to the Claims

1. (Currently amended) A compound of the formula

$$R^{6} \xrightarrow{X} R^{5} NR^{3}R^{4} NR^{1}R^{2}$$
(I)

where

X is methylene or hydroxymethylene;

R¹ a) is hydrogen; or

b) is C_1 - C_8 -alkyl, C_3 - C_8 -cycloalkyl, C_1 - C_8 -alkanoyl, C_1 - C_8 -alkoxycarbonyl, $\frac{\text{aryl-}C_0}{C_4$ -alkyl-or heterocyclyl- C_0 - C_4 -alkyl, which radicals may be substituted by 1-4 C_1 - C_8 -alkyl, halogen, cyano, oxide, oxo, trifluoromethyl, C_1 - C_8 -alkoxy, C_1 - C_8 -alkoxycarbonyl, aryl or heterocyclyl;

 R^2 a) is C_1 - C_8 -alkyl, C_3 - C_8 -cycloalkyl, C_1 - C_8 -alkylsulphonyl, C_3 - C_8 -cycloalkylsulphonyl, aryl- C_0 - C_8 -alkylsulphonyl, heterocyclylsulphonyl, C_3 - C_{12} -cycloalkyl- C_1 - C_8 -alkanoyl, C_3 - C_{12} -cycloalkyl- C_3 - C_8 -cycloalkanoyl, aryl- C_1 - C_8 -alkanoyl, heterocyclyl- C_1 - C_8 -alkanoyl, aryl- C_3 - C_8 -cycloalkanoyl, C_1 - C_8 -alkanoyl, C_1 - C_8 -alkoxycarbonyl, optionally N-mono or N,N-di- C_1 - C_8 -alkylated carbamoyl- C_0 - C_8 -alkyl, $\frac{aryl-C_0}{C_4}$ -alkyl- or heterocyclyl- C_0 - C_4 -alkyl, which radicals may be substituted by 1-4 C_1 - C_8 -alkyl, C_3 - C_8 -cycloalkyl, C_3 - C_8 -cycloalkoxy, amino, C_1 - G_9 -alkylamino, di- G_1 - G_9 -alkylamino, G_0 - G_9 -alkylamino, halogen, cyano, hydroxyl, oxide, oxo, trifluoromethyl, G_1 - G_9 -alkoxy, optionally N-mono or N,N-di- G_1 - G_9 -alkylated carbamoyl, G_1 - G_9 -alkoxycarbonyl, G_1 - G_9 -alkylenedioxy, aryl or heterocyclyl; or

b) together with R₁ and the nitrogen atom to which they are bonded, is a saturated or partly unsaturated 4-8-membered heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom or an -SO- or -SO2- group, and the additional nitrogen

atom may optionally be substituted by C₁-C₈-alkyl, C₁-C₈-alkanoyl, C₁-C₈-alkoxycarbonyl, aryl or heterocyclyl radicals, in which case this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 members and the second ring may also contain a nitrogen, oxygen or sulphur atom or an –SO- or –SO2- group, and the nitrogen atom of the second ring may optionally be substituted by C₁-C₈-alkyl, C₁-C₈-alkanoyl, C₁-C₈-alkoxycarbonyl, aryl or heterocyclyl radicals, and all ring systems mentioned may be substituted by 1-4 C₁-C₈-alkyl, halogen, hydroxyl, oxide, oxo, trifluoromethyl, C₁-C₈-alkoxy, C₁-C₈-alkoxy-C₁-C₈-alkoxy-C₁-C₈-alkoxy-C₁-C₈-alkoxycarbonyl-amino, C₁-C₈-alkylcarbonylamino, C₁-C₈-alkylamino, N,N-di-C₁-C₈-alkylamino, aryl-C₀-C₄-alkyl, aryloxy-C₀-C₄-alkyl, aryloxy-C₀-C₄-alkyl-C₁-C₈-alkoxy, aryloxy-C₀-C₄-alkyl-C₁-C₈-alkoxy, heterocyclyl-C₀-C₄-alkyl, heterocyclyloxy-C₀-C₄-alkyl, heterocyclyl-C₀-C₄-alkyl-C₁-C₈-alkoxy;

R³ is hydrogen, C₁-C₄-alkyl, C₁-C₈-alkoxycarbonyl or C₁-C₈-alkanoyl;

R⁴ is hydrogen, C₁-C₄-alkyl, C₁-C₈-alkoxycarbonyl or C₁-C₈-alkanoyl;

 R^5 are each independently hydrogen, C_1 - C_8 -alkyl or, together with the carbon atom to which they are bonded, are a C_3 - C_8 -cycloalkylidene radical;

(A) R⁶ is a heterocyclyl radical which is substituted by from one to four radicals selected from C₁-C₆-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkoxy, C₃₋₈-cycloalkoxy-C₁₋₆-alkyl, C₃₋₈-cycloalkoxy-C₁₋₆-alkyl, C₃₋₈-cycloalkoxy-C₁₋₆-alkyl, C₁₋₆-alkylamino, di-C₁-C₆-alkylamino, amino-C₁₋₆-alkyl, amino-C₂₋₇-alkoxy, polyhalo-C₁₋₆-alkyl, polyhalo-C₂₋₇-alkoxy, nitro, amino, C₂-C₆-alkenyl, C₁-C₆-alkoxy, C₁-C₆-alkanoyloxy, hydroxyl, halogen, oxide, oxo, cyano, carbamoyl, carboxy, C₁-C₆-alkylenedioxy, phenyl, phenoxy, phenylthio, phenyl-C₁-C₆-alkyl or phenyl-C₁-C₆-alkoxy, each of which are optionally substituted by halogen, C₁-C₆-alkyl, C₁₋₆-alkoxy, hydroxyl, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino, C₁₋₆-alkoxycarbonyl, hydroxy-C₁₋₆-alkyl or trifluoromethyl, pyridylcarbonylamino-C₁₋₆-alkyl, C₂₋₇-alkenyloxy, C₁₋₆-alkoxy-C₁₋₆-alkoxy, C₁₋₆-alkoxy, hydroxybenzyloxy, methylenedioxybenzyloxy, dioxolanyl-C₁₋₆-alkoxy, C₃₋₈-cycloalkyl-C₁₋₆-alkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkoxy, hydroxy-C₂₋₇-alkoxy, carbamoyloxy-C₂₋₇-alkoxy,

pyridylcarbamoyloxy-C₂₋₇-alkoxy, benzoyloxy-C₂₋₇-alkoxy, C₁₋₆-alkoxycarbonyl, C₁₋₆-alkylcarbonylamino, C₁₋₆-alkylcarbonylamino-C₁₋₆-alkyl, C₁₋₆alkylcarbonylamino-C₂₋₇-alkoxy, (N-C₁₋₆-alkyl)-C₁₋₆-alkylcarbonylamino-C₁₋₆alkyl, (N-C₁₋₆-alkyl)-C₁₋₆-alkylcarbonylamino-C₂₋₇-alkoxy, C₃₋₈cycloalkylcarbonylamino-C₁₋₆-alkyl, C₃₋₈-cycloalkylcarbonylamino-C₂₋₇-alkoxy, C_{1-6} -alkoxy- C_{1-6} -alkyl, hydroxy- C_{1-6} -alkyl, hydroxy- C_{2-7} -alkoxy- C_{1-6} -alkyl, hydroxy-C₂₋₇-alkoxy-C₁₋₆-alkoxy, C₁₋₆-alkoxycarbonylamino-C₁₋₆-alkyl, C₁₋₆alkoxycarbonylamino-C₂₋₇-alkoxy, C₁₋₆-alkylaminocarbonylamino-C₁₋₆-alkyl, C₁₋₆alkylaminocarbonylamino-C₂₋₇-alkoxy, C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkyl, C₁₋₆alkylaminocarbonyl-C₁₋₆-alkoxy, C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkoxy-C₁₋₆-alkyl, di-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkyl, di-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkoxy, C₁₋₆ 6-alkylcarbonyloxy-C₁₋₆-alkyl, C₁₋₆-alkylcarbonyloxy-C₂₋₆-alkoxy, cyano-C₁₋₆alkyl, cyano-C₁₋₆-alkoxy, 2-oxooxazolidinyl-C₁₋₆-alkyl, 2-oxo-oxazolidinyl-C₁₋₆alkoxy, C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl-C₁₋₆-alkoxy, C₁₋₆alkylsulphonylamino-C₁₋₆-alkyl, C₁₋₆-alkylsulphonylamino-C₂₋₇-alkoxy, (N-C₁₋₆alkyl)-C₁₋₆-alkylsulphonylamino-C₁₋₆-alkyl, (N-C₁₋₆-alkyl)-C₁₋₆alkylsulphonylamino-C₂₋₇-alkoxy, C₁₋₆-alkylamino-C₁₋₆-alkyl, C₁₋₆-alkylamino-C₂-7-alkoxy, di-C₁₋₆-alkylamino-C₁₋₆-alkyl, di-C₁₋₆-alkylamino-C₂₋₇-alkoxy, C₁₋₆alkylsulphonyl-C₁₋₆-alkyl, C₁₋₆-alkylsulphonyl-C₁₋₆-alkoxy, carboxy-C₁₋₆-alkyl, carboxy-C₁₋₆-alkoxy, carboxy-C₁₋₆-alkoxy-C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆alkylcarbonyl, acyl-C₁₋₆-alkoxy-C₁₋₆-alkyl, (N-C₁₋₆-alkyl)-C₁₋₆alkoxycarbonylamino, (N-hydroxy)-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkyl, (Nhydroxy)-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkoxy, (N-hydroxy)aminocarbonyl-C₁₋₆alkyl, (N-hydroxy)aminocarbonyl-C₁₋₆-alkoxy, C₁₋₆-alkoxy-aminocarbonyl-C₁₋₆alkyl, 6-alkoxyaminocarbonyl-C₁₋₆-alkoxy, (N-C₁₋₆-alkoxy)-C₁₋₆alkylaminocarbonyl-C₁₋₆-alkyl, (N-C₁₋₆-alkoxy)-C₁₋₆-alkylaminocarbonyl-C₁₋₆alkoxy, (N-acyl)-C₁₋₆-alkoxy-C₁₋₆-alkylamino, C₁₋₆-alkoxy-C₁₋₆-alkylcarbamoyl, $(N-C_{1-6}-alkyl)-C_{1-6}-alkoxy-C_{1-6}-alkylcarbamoyl, C_{1-6}-alkoxy-C_{1-6}-alkylcarbonyl,$ C₁₋₆-alkoxy-C₁₋₆-alkylcarbonylamino, (N-C₁₋₆-alkyl)-C₁₋₆-alkoxy-C₁₋₆alkylcarbonylamino, 1-C₁₋₆-alkoxy-C₁₋₆-alkylimidazol-2-yl, 1-C₁₋₆-alkoxy-C₁₋₆alkyltetrazol-5-yl, 5-C₁₋₆-alkoxy-C₁₋₆-alkyltetrazol-1-yl, 2-C₁₋₆-alkoxy-C₁₋₆-alkyl-4oxoimidazol-1-yl, carbamoyl-C₁₋₆-alkyl, carbamoyl-C₁₋₆-alkoxy, C₁₋₆alkylcarbamoyl, di- C_{1-6} -alkylcarbamoyl, C_{1-6} -alkylsulphonyl, C_{1-6} -alkylamidinyl, acetamidinyl-C₁₋₆-alkyl, O-methyloximyl-C₁₋₆-alkyl, O,N-dimethylhydroxylamino-C₁₋₆-alkyl, C₃₋₆-cycloalkyl-C₁₋₆-alkanoyl, aryl-C₁₋₆-alkanoyl or heterocyclyl-C₁₋₆alkanoyl, or else pyridyl, pyridyloxy, pyridylthio, pyridylamino, pyridyl-C₁₋₆-alkyl, pyridyl-C₁₋₆-alkoxy, pyrimidinyl, pyrimidinyloxy, pyrimidinylthio, pyrimidinylamino, pyrimidinyl-C₁₋₆-alkyl, pyrimidinyl-C₁₋₆-alkoxy, thienyl, thienyl-C₁₋₆-alkyl, thienyl-C₁₋₆-alkoxy, furyl, furyl-C₁₋₆-alkyl or furyl-C₁₋₆-alkoxy, each of which is optionally substituted by halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or dihydroxy-C₁₋₆-alkylaminocarbonyl, piperidinoalkyl, piperidinoalkoxy, piperidinoalkoxyalkyl, morpholinoalkyl, morpholinoalkoxy, morpholinoalkoxyalkyl, piperazinoalkyl, piperazinoalkoxy, piperazinoalkoxyalkyl, [1,2,4]-triazol-1-ylalkyl, [1,2,4]-triazol-1-ylalkoxy, [1,2,4]-triazol-4-ylalkyl, [1,2,4]-triazol-4-ylalkoxy, [1,2,4]-oxadiazol-5-ylalkyl, [1,2,4]-oxadiazol-5ylalkoxy, 3-methyl-[1,2,4]-oxadiazol-5-ylalkyl, 3-methyl-[1,2,4]-oxadiazol-5ylalkoxy, 5-methyl-[1,2,4]-oxadiazol-3-ylalkyl, 5-methyl-[1,2,4]-oxadiazol-3ylalkoxy, tetrazol-1-ylalkyl, tetrazol-1-ylalkoxy, tetrazol-2-ylalkyl, tetrazol-2ylalkoxy, tetrazol-5-ylalkyl, tetrazol-5-ylalkoxy, 5-methyl-tetrazol-1-ylalkyl, 5methyl-tetrazol-1-ylalkoxy, thiazol-4-ylalkyl, thiazol-4-ylalkoxy, oxazol-4-ylalkyl, oxazol-4-ylalkoxy, 2-oxo-pyrrolidinylalkyl, 2-oxo-pyrrolidinylalkoxy, imidazolylalkyl, imidazolylalkoxy, 2-methyl-imidazolylalkyl, 2-methylimidazolylalkoxy, N-methylpiperazinoalkyl, N-methylpiperazinoalkoxy, Nmethylpiperazinoalkoxyalkyl, dioxolanyl, dioxanyl, dithiolanyl, dithianyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrrolyl, 4-methylpiperazinyl, morpholinyl, thiomorpholinyl, 2-hydroxymethylpyrrolidinyl, 3-hydroxypyrrolidinyl, 3,4dihydroxypyrrolidinyl, 3-acetamidomethylpyrrolidinyl, 3-C₁₋₆-alkoxy-C₁₋₆-alkylpyrrolidinyl, 4-hydroxypiperidinyl, 4-oxopiperidinyl, 3,5-dimethylmorpholinyl, 4,4-dioxothiomorpholinyl, 4-oxothiomorpholinyl, 2,6-dimethylmorpholinyl, 2-oxoimidazolidinyl, 2-oxooxazolidinyl, 2-oxopyrrolidinyl, 2-oxo-[1,3]oxazinyl, 2-oxotetrahydropyrimidinyl and the -O-CH₂CH(OH)CH₂NR_x radical where NR_x is a

mono- or di-C₁₋₆-alkylamino, piperidino, morpholino, piperazino or N-methylpiperazino radical; or

(B) R⁶ is phenyl substituted by C₁-C₆-alkylenedioxy, furyl, thienyl, pyridyl, pyrimidyl, indolyl, quinolinyl, pyrazinyl, triazolyl, imidazolyl, benzothiazolyl, pyranyl, tetrahydropyranyl, azetidinyl, morpholinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, quinazolinyl, quinoxalinyl, isoquinolyl, benzo[b]thienyl, isobenzofuranyl, benzoimidazolyl, 2-oxobenzoimidazolyl, oxazolyl, thiazolyl, pyrrolyl, pyrazolyl, triazinyl, dihydrobenzofuranyl, 2-oxodihydrobenzo [d][1,3]oxazinyl, 4-oxodihydroimidazolyl, 5-oxo-4H[1,2,4]triazinyl, 3-oxo-4Hbenzo [1,4] thiazinyl, tetrahydroquinoxalinyl, 1,1,3-trioxodihydro-2H-1 λ^6 benzo[1,4]thiazinyl, 1-oxopyridyl, dihydro-3H-benzo[1,4]oxazinyl, 3,4-dihydro-2H-benzo[1,4]oxazinyl, 2-oxotetrahydrobenzo[e][1,4]diazepinyl, 2-oxodihydrobenzo[e][1,4]diazepinyl, 1H-pyrrolizinyl, phthalazinyl, 1-oxo-3Hisobenzofuranyl, 4-oxo-3H-thieno[2,3-d] pyrimidinyl, 3-oxo-4Hbenzo[1,4]oxazinyl, [1,5]naphthyridyl, dihydro-2H-benzo [1,4]thiazinyl, 1,1dioxodihydro-2H-benzo[1,4]thiazinyl, 2-oxo-1H-pyrido[2,3-b] [1,4]oxazinyl, dihydro-1H-pyrido[2,3-b][1,4]oxazinyl, 1H-pyrrolo[2,3-b]pyridyl, benzo [1,3]dioxolyl, benzooxazolyl, 2-oxobenzooxazolyl, 2-oxo-1,3-dihydroindolyl, 2,3-dihydroindolyl, indazolyl, benzofuranyl, dioxolanyl, dioxanyl, dithiolanyl, dithianyl, pyrrolidinyl, piperidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl, thiomorpholinyl, 2-hydroxymethylpyrrolidinyl, 3-hydroxypyrrolidinyl, 3,4dihydroxypyrrolidinyl, 4-hydroxypiperidinyl, 4-oxopiperidinyl, 3,5dimethylmorpholinyl, 4,4-dioxothiomorpholinyl, 4-oxothiomorpholinyl, 2.6dimethylmorpholinyl, tetrahydropyranyl, 2-oxoimidazolidinyl, 2-oxooxazolidinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxo[1,3]oxazinyl, 2-oxoazepanyl, or 2oxotetrahydropyrimidinyl;

or a prodrug thereof, which on *in vivo* application, release a compound of formula (1) by a chemical or physiological process,

or in which one or more atoms have been replaced by their stable, non-radioactive isotopes, or a salt thereof.

2. (Previously presented) The compound according to Claim 1, characterized in that it corresponds to the formula (la)

$$R^6$$
 X
 NR^1R^2
 R^5
 NR^3R^4
(Ia)

where the substituents are each as defined in Claim 1.

- 3. (Currently amended) The compound according to Claim 1 or 2, in which R^2 is C_1 - C_8 -alkyl, C_3 - C_8 -cycloalkyl, C_1 - C_8 -alkylsulphonyl, C_3 - C_8 -cycloalkylsulphonyl, C_3 - C_8 -cycloalkylsulphonyl, C_3 - C_1 -cycloalkyl- C_1 - C_8 -alkanoyl, C_3 - C_1 -cycloalkyl- C_3 - C_8 -cycloalkanoyl, aryl- C_1 - C_8 -alkanoyl, heterocyclyl- C_1 - C_8 -alkanoyl, or C_1 - C_8 -alkanoyl-or aryl- C_0 - C_4 -alkyl, which radicals may be substituted by 1-4 C_1 - C_8 -alkyl, C_3 - C_8 -cycloalkyl, C_3 - C_8 -cycloalkoxy, C_0 - C_6 -alkylcarbonylamino, halogen, cyano, hydroxyl, oxide, trifluoromethyl, C_1 - C_8 -alkoxy or optionally N-mono- or N,N-di- C_1 - C_8 -alkylated carbamoyl.
- 4. (Previously presented) The compound according to Claim 1 or 2, in which R^{1} a) is hydrogen; or
 - b) is C₁-C₈-alkyl or C₃-C₈-cycloalkyl;

 R^2 a) is C_1 - C_8 -alkyl, C_3 - C_8 -cycloalkyl, C_1 - C_8 -alkanoyl, heterocyclyl- C_1 - C_8 -alkanoyl, C_3 - C_{12} -cycloalkyl- C_1 - C_8 -alkanoyl or aryl- C_1 - C_8 -alkanoyl, which radicals may be substituted by 1-4 C_1 - C_8 -alkyl, C_1 - C_8 -alkylamino, cyano, halogen, hydroxyl, C_1 - C_6 -alkanoylamino, C_1 - C_8 -alkoxy, oxide, oxo, trifluoromethyl or aryl; or

- b) together with R¹ and the nitrogen atom to which they are bonded, is a saturated or partly unsaturated, 4-8-membered heterocyclic ring which may contain an additional nitrogen or oxygen atom, in which case the additional nitrogen atom may optionally be substituted by C₁-C₈-alkyl or C₁-C₈-alkanoyl, in which case this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 ring members and the second ring may also contain a nitrogen or oxygen atom, and the nitrogen atom of the second ring may optionally be substituted by C₁-C₈-alkyl or C₁-C₈-alkanoyl, and all ring systems mentioned may be substituted by 1-4 C₁-C₈-alkyl, hydroxyl, oxide, oxo, C₁-C₈-alkoxy, C₁-C₈-alkoxy, C₁-C₈-alkoxy, C₁-C₈-alkoxy, C₁-C₈-alkoxy, C₁-C₈-alkoxy, C₁-C₈-alkoxy, C₁-C₈-alkoxy.
- 5. (Previously presented) The compound according to Claim 1 or 2, in which X is methylene;
- R¹ a) is hydrogen; or
 - b) is C_1 - C_8 -alkyl or C_3 - C_8 -cycloalkyl;
- R^2 a) is C_1 - C_8 -alkyl, C_3 - C_8 -cycloalkyl, C_1 - C_8 -alkanoyl, heterocyclyl- C_1 - C_8 -alkanoyl, C_3 - C_{12} -cycloalkyl- C_1 - C_8 -alkanoyl or aryl- C_1 - C_8 -alkanoyl, which radicals may be substituted by 1-4 C_1 - C_8 -alkyl, C_1 - C_8 -alkylamino, cyano, halogen, hydroxyl, C_1 - C_6 -alkanoylamino, C_1 - C_8 -alkoxy, oxide, oxo, trifluoromethyl or aryl; or
- b) together with R¹ and the nitrogen atom to which they are bonded, is a saturated or partly unsaturated, 4-8-membered heterocyclic ring which may contain an additional nitrogen or oxygen atom, in which case the additional nitrogen atom may optionally be substituted by C₁-C₈-alkyl or C₁-C₈-alkanoyl, in which case this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 ring members and the second ring may also contain a nitrogen or oxygen atom, and the nitrogen atom of the second ring may optionally be substituted by C₁-C₈-alkyl or C₁-C₈-alkanoyl, and all ring systems mentioned may be substituted by 1-4 C₁-C₈-alkyl, hydroxyl, oxide, oxo, C₁-C₈-alkoxy, C₁-C₈-alkoxy, C₁-C₈-alkoxy, C₁-C₈-alkoxy-C₁-C₈-alkoxy, C₁-C₈-alkoxy-C₁-C₈-alkoxy;

R³ is hydrogen;

 R^4 is hydrogen; R^5 are each independently hydrogen or C_1 - C_8 -alkyl; and R^6 is as defined in Claim 1.

(Previously presented) The compound according to Claim 1 or 2, in which the R⁶ 6. radical is selected from the group consisting of furyl, thienyl, pyridyl, pyrimidyl, indolyl, quinolinyl, benzoimidazolyl, di-C₁₋₆-alkoxypyrimidinyl, 2- and 5-benzo[b]thienyl, 6- and 7-isoquinolyl, 6- and 7-tetrahydroquinolyl, 6- and 7-tetrahydroisoquinolyl, 6quinoxalinyl, 6- and 7-quinazolinyl, dihydro-3H-benzo[1,4]oxazinyl, 3,4-dihydro-2Hbenzo[1,4]oxazinyl, 3-oxo-4H-benzo[1,4]oxazinyl, 2-oxobenzooxazolyl, 2-oxo-1,3dihydroindolyl, 2,3-dihydroindolyl, indazolyl or benzofuranyl; and 6- and 7-quinolyl, 6- and 7-isoquinolyl, 6- and 7-tetrahydroquinolyl, oxotetrahydroquinolyl, 6- and 7-tetrahydroisoquinolyl, 6-quinoxalinyl, 6- and 7quinazolinyl, indolyl, dihydro-3H-benzo[1,4]oxazinyl, 3,4-dihydro-2Hbenzo[1,4]oxazinyl, 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazinyl, 3-oxo-4Hbenzo[1,4]oxazinyl, 2-oxobenzooxazolyl, 2-oxo-2,3-dihydrobenzooxazolyl, 2-oxo-1,3dihydroindolyl, 2,3-dihydroindolyl, indazolyl, benzofuranyl, 2,3-dihydrobenzothiazinyl, imidazolyl, benzoimidazolyl, pyridinyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-b]pyridinyl, [1,2,3]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,5-a]pyridinyl or naphthyl or cyclohexenophenyl, each of which is substituted by from one to four radicals selected from C₁₋₆-alkyl, cyano, oxo, oxide, trifluoromethyl, hydroxyl, halogen, carbamoyl, carboxy, C₁₋₆-alkoxy, hydroxy-C₂₋₇-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkoxy, di-C₁₋₆alkylamino, 2,3-dihydroxypropoxy, 2,3-dihydroxypropoxy-C₁₋₆-alkoxy, 2,3dimethoxypropoxy, methoxybenzyloxy, hydroxybenzyloxy, phenethyloxy, methylenedioxybenzyloxy, dioxolanyl-C₁₋₆-alkoxy, cyclopropyl-C₁₋₆-alkoxy, pyridylcarbamoyloxy-C₁₋₆-alkoxy, 3-morpholino-2-hydroxypropoxy, benzyloxy-C₁₋₆alkoxy, picolyloxy, C₁₋₆-alkoxycarbonyl, C₁₋₆-alkoxy-C₁₋₆-alkoxy-C₁₋₆-alkyl, C₁₋₆alkylcarbonylamino, C₁₋₆-alkylcarbonylamino-C₁₋₆-alkyl, C₁₋₆-alkylcarbonylamino-C₁₋₆alkoxy, (N-C₁₋₆-alkyl)-C₁₋₆-alkylcarbonylamino-C₁₋₆-alkyl, (N-C₁₋₆-alkyl)-C₁₋₆-

alkylcarbonylamino-C₁₋₆-alkoxy, C₃₋₆-cycloalkylcarbonylamino-C₁₋₆-alkyl, C₃₋₆cycloalkylcarbonylamino-C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, hydroxy-C₂₋₇-alkoxy-C₁₋₆-alkyl, hydroxy-C₂₋₇-alkoxy-C₁₋₆-alkoxy, C₁₋₆-alkoxycarbonylamino-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonylamino-C₂₋₇-alkoxy, C₁₋₆alkylaminocarbonylamino-C₁₋₆-alkyl, C₁₋₆-alkylaminocarbonylamino-C₂₋₇-alkoxy, C₁₋₆alkylaminocarbonyl-C₁₋₆-alkyl, C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkoxy, C₁₋₆alkylaminocarbonyl-C₁₋₆-alkoxy-C₁₋₆-alkyl, di-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkyl, di-C₁. 6-alkylaminocarbonyl-C₁₋₆-alkoxy, C₁₋₆-alkylcarbonyloxy-C₁₋₆-alkyl, C₁₋₆alkylcarbonyloxy-C₁₋₆-alkoxy, cyano-C₁₋₆-alkyl, cyano-C₁₋₆-alkoxy, 2-oxooxazolidinyl-C₁₋₆-alkyl, 2-oxooxazolidinyl-C₁₋₆-alkoxy, C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl, C₁₋₆alkoxycarbonyl-C₁₋₆-alkoxy, C₁₋₆-alkylsulphonylamino-C₁₋₆-alkyl, C₁₋₆alkylsulphonylamino-C₂₋₇-alkoxy, (N-C₁₋₆-alkyl)-C₁₋₆-alkylsulphonylamino-C₁₋₆-alkyl, (N-C₁₋₆-alkyl)-C₁₋₆-alkylsulphonylamino-C₁₋₆-alkoxy, C₁₋₆-alkylamino-C₁₋₆-alkyl, C₁₋₆alkylamino-C₂₋₇-alkoxy, di-C₁₋₆-alkylamino-C₁₋₆-alkyl, Di-C₁₋₆-alkylamino-C₂₋₇-alkoxy, C_{1-6} -alkylsulphonyl- C_{1-6} -alkyl, C_{1-6} -alkylsulphonyl- C_{1-6} -alkoxy, carboxy- C_{1-6} -alkyl, carboxy-C₁₋₆-alkoxy, carboxy-C₁₋₆-alkoxy-C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkylcarbonyl, acyl-C₁₋₆-alkoxy-C₁₋₆-alkyl, (N-C₁₋₆-alkyl)-C₁₋₆-alkoxy-carbonylamino, (N-hydroxy)-C₁₋₆alkylaminocarbonyl-C₁₋₆-alkyl, (N-hydroxy)-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkoxy, (Nhydroxy)aminocarbonyl-C₁₋₆-alkyl, (N-hydroxy)aminocarbonyl-C₁₋₆-alkoxy, C₁₋₆alkoxyaminocarbonyl-C₁₋₆-alkyl, 6-alkoxy-aminocarbonyl-C₁₋₆-alkoxy, (N-C₁₋₆-alkoxy)-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkyl, (N-C₁₋₆-alkoxy)-C₁₋₆-alkylaminocarbonyl-C₁₋₆alkoxy, (N-acyl)-C₁₋₆-alkoxy-C₁₋₆-alkylamino, C₁₋₆-alkoxy-C₁₋₆-alkylcarbamoyl, (N-C₁₋₆alkyl)-C₁₋₆-alkoxy-C₁₋₆-alkylcarbamoyl, C₁₋₆-alkoxy-C₁₋₆-alkylcarbonyl, C₁₋₆-alkoxy-C₁₋₆alkylcarbonylamino, (N-C₁₋₆-alkyl)-C₁₋₆-alkoxy-C₁₋₆-alkylcarbonylamino, 1-C₁₋₆-alkoxy-C₁₋₆-alkylimidazol-2-yl, 1-C₁₋₆-alkoxy-C₁₋₆-alkyltetrazol-5-yl, 5-C₁₋₆-alkoxy-C₁₋₆alkyltetrazol-1-yl, 2-C₁₋₆-alkoxy-C₁₋₆-alkyl-4-oxoimidazol-1-yl, carbamoyl-C₁₋₆-alkyl, carbamoyl-C₁₋₆-alkoxy, C₁₋₆-alkylcarbamoyl, di-C₁₋₆-alkylcarbamoyl, C₁₋₆alkylsulphonyl, piperidinoalkyl, piperidinoalkoxy, piperidinoalkoxyalkyl, morpholinoalkyl, morpholinoalkoxy, morpholinoalkoxyalkyl, piperazinoalkyl, piperazinoalkoxy, piperazinoalkoxyalkyl, [1,2,4]-triazol-1-ylalkyl, [1,2,4]-triazol-1ylalkoxy, [1,2,4]-triazol-4-ylalkyl, [1,2,4]-triazol-4-ylalkoxy, [1,2,4]-oxadiazol-5-ylalkyl, [1,2,4]-oxadiazol-5-ylalkoxy, 3-methyl-[1,2,4]-oxadiazol-5-ylalkyl, 3-methyl-[1,2,4]oxadiazol-5-ylalkoxy, 5-methyl-[1,2,4]-oxadiazol-3-ylalkyl, 5-methyl-[1,2,4]-oxadiazol-3-ylalkoxy, tetrazol-1-ylalkyl, tetrazol-1-ylalkoxy, tetrazol-2-ylalkyl, tetrazol-2-ylalkoxy, tetrazol-5-ylalkyl, tetrazol-5-ylalkoxy, 5-methyltetrazol-1-ylalkyl, 5-methyltetrazol-1ylalkoxy, thiazol-4-ylalkyl, thiazol-4-ylalkoxy, oxazol-4-ylalkyl, oxazol-4-ylalkoxy, 2oxopyrrolidinylalkyl, 2-oxopyrrolidinylalkoxy, imidazolylalkyl, imidazolylalkoxy, 2methylimidazolylalkyl, 2-methylimidazolylalkoxy, N-methylpiperazinoalkyl, Nmethylpiperazinoalkoxy, N-methylpiperazinoalkoxyalkyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrrolyl, 4-methylpiperazinyl, morpholinyl, thiomorpholinyl, 2hydroxymethylpyrrolidinyl, 3-hydroxypyrrolidinyl, 3,4-dihydroxypyrrolidinyl, 3acetamidomethylpyrrolidinyl, 3-C₁₋₆-alkoxy-C₁₋₆-alkyl-pyrrolidinyl, 4hydroxypiperidinyl, 4-oxopiperidinyl, 3,5-dimethylmorpholinyl, 4,4dioxothiomorpholinyl, 4-oxothiomorpholinyl, 2,6-dimethylmorpholinyl, 2oxoimidazolidinyl, 2-oxooxazolidinyl, 2-oxopyrrolidinyl, 2-oxo-[1,3]oxazinyl and 2oxotetrahydropyrimidinyl.

7. (Currently amended) A compound of the formula

$$R^{6}$$
 X
 R^{5}
 R^{5}
 $NR^{3}R^{4}$
 (I)

where

X is methylene or hydroxymethylene; R¹ a) is hydrogen; or b) is C_1 - C_8 -alkyl, C_3 - C_8 -cycloalkyl, C_1 - C_8 -alkanoyl, C_1 - C_8 -alkoxycarbonyl, anyl- C_0 - C_4 -alkyl, which radicals may be substituted by 1-4 C_1 - C_8 -alkyl, halogen, cyano, oxide. oxo, trifluoromethyl, C_1 - C_8 -alkoxy, C_1 - C_8 -alkoxy, aryl or heterocyclyl:

 R^2 a) is C_1 – C_8 -alkyl, C_3 – C_8 -cycloalkyl, C_1 – C_8 -alkylsulphonyl, C_3 – C_8 -cycloalkylsulphonyl, aryl- C_0 – C_8 -alkylsulphonyl, heterocyclylsulphonyl, C_3 – C_{12} -cycloalkyl- C_1 – C_8 -alkanoyl, C_3 – C_1 -cycloalkyl- C_3 – C_8 -cycloalkanoyl, aryl- C_3 – C_8 -alkanoyl, heterocyclyl- C_1 – C_8 -alkanoyl, aryl- C_3 – C_8 -cycloalkanoyl, C_1 – C_8 -alkoxycarbonyl, optionally N-mono or N,N-di- C_1 – C_8 -alkylated carbamoyl- C_0 – C_8 -alkyl, aryl- C_0 – C_8 -alkyl or heterocyclyl- C_0 – C_4 -alkyl, which radicals may be substituted by 1–4 C_1 – C_8 -alkyl, C_3 – C_8 -cycloalkyl, C_3 – C_8 -cycloalkyl, C_3 – C_8 -cycloalkoxy, amino, $C_{1.6}$ -alkylamino, di- $C_{1.6}$ -alkylamino, C_0 – C_8 -alkylcarbonylamino, halogen, cyano, hydroxyl, oxide, oxo, trifluoromethyl, C_1 – C_8 -alkoxy, optionally N-mono or N,N-di- C_1 – C_8 -alkylated carbamoyl, C_1 - C_8 -alkoxycarbonyl, C_1 - C_8 -alkylenedioxy, aryl or heterocyclyl; or

b) together with R₁ and the nitrogen atom to which they are bonded, is a saturated or partly unsaturated 4-8-membered heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom or an –SO- or –SO2- group, and the additional nitrogen atom may optionally be substituted by C₁-C₈-alkyl, C₁-C₈-alkarioyl, C₁-C₈-alkoxycarbonyl, anyl or heterocyclyl radicals, in which case this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 members and the second ring may also contain a nitrogen, oxygen or sulphur atom or an –SO- or –SO2- group, and the nitrogen atom of the second ring may optionally be substituted by C₁-C₈-alkyl, C₁-C₉-alkanoyl, C₁-C₈-alkoxycarbonyl, anyl or heterocyclyl radicals, and all ring systems mentioned may be substituted by 1-4 C₁-C₈-alkyl, halogen, hydroxyl, oxide, oxo, trifluoromethyl, C₁-C₈-alkoxy, C₁-C₈-alkoxy-C₁-C₈-alkoxy-C₁-C₈-alkoxy-C₁-C₈-alkoxy, C₁-C₈-alkoxy-C₁-C₈-alkylamino, N,N-di-C₁-C₈-alkylamino, anyl-C₉-C₄-alkyl, aryloxy-C₉-C₄-alkyl, aryl-C₁-C₆-alkyl-C₁-C₈-alkoxy, heterocyclyl-C₉-C₄-alkyl, heterocyclyloxy-C₉-C₄-alkyl, heterocyclyl-C₉-C₄-alkyl-C₁-C₈-alkoxy; alkoxy or heterocyclyloxy-C₉-C₄-alkyl-C₁-C₈-alkoxy;

 R^3 is hydrogen, C_1 - C_4 -alkyl, C_1 - C_8 -alkoxycarbonyl or C_1 - C_8 -alkanoyl; R^4 is hydrogen, C_1 - C_6 -alkyl, C_1 - C_8 -alkoxycarbonyl or C_1 - C_6 -alkanoyl;

 R^{s} are each independently hydrogen. C_{1} - C_{8} -alkyl or, together with the carbon atom to which they are bonded, are a C_{3} - C_{8} -cycloalkylidene radical;

 R^6 is an unsubstituted polycyclic, unsaturated hydrocarbon radical excluding naphthyl, or a polycyclic, unsaturated hydrocarbon radical excluding naphthyl, which is substituted by from one to four radicals selected from C_1 -

 C_{6} -alkyl, $C_{3.6}$ -cycloalkyl, $C_{3.6}$ -cycloalkoxy, $C_{3.6}$ -cycloalkoxy- $C_{1.6}$ -alkyl, $C_{3.6}$ -cycloalkoxy- C_{1-6} -alkoxy, C_1 - C_6 -alkylamino, di- C_1 - C_6 -alkylamino, amino- C_{1-6} -alkyl, amino- C_{2-7} -alkoxy, polyhalo- C_{1-6} -alkyl, polyhalo- C_{2-7} -alkoxy, nitro, amino, C_{2-} C₆-alkenyl, C_{1-} C₆-alkoxy, C_{1-} C_0 -alkanoyloxy, hydroxyl, halogen, oxide, oxo, cyano, carbamoyl, carboxy, C_1 - C_6 alkylenedioxy, phenyl, phenoxy, phenylthio, phenyl- C_1 - C_8 -alkyl or phenyl- C_1 - C_8 -alkoxy, each of which are optionally substituted by halogen, C_1 - C_6 -alkyl, C_{1-8} -alkoxy, hydroxyl, C_1 - C_6 -alkylamino, di- C_1 - C_6 -alkylamino, C_{1-6} -alkoxycarbonyl, hydroxy- C_{1-6} -alkyl or trifluoromethyl, pyrkdylcarbonylamino- $C_{1-\theta}$ -alkyl, $C_{2-\gamma}$ -alkenyloxy, $C_{1-\theta}$ -alkoxy- $C_{1-\theta}$ alkoxy, C_{1-6} -alkoxy- C_{1-6} -alkoxy- C_{1-6} -alkyl, methoxybenzyloxy, hydroxybenzyloxy, methylenedioxybenzyloxy, dioxolanyl- C_{1-6} -alkoxy, C_{3-6} -cycloalkyl- C_{1-6} -alkyl, C_{3-6} cycloalkyl- C_{1-8} -alkoxy, hydroxy- C_{2-7} -alkoxy, carbamoyloxy- C_{2-7} -alkoxy, pyridyfcarbamoyfoxy- $C_{2,7}$ -alkoxy, benzoyfoxy- $C_{2,7}$ -alkoxy, C_{1-6} -alkoxycarbonyl, C_{1-6} alkylcarbonylamino. C_{1-8} -alkylcarbonylamino- C_{1-8} -alkyl, C_{1-8} -alkylcarbonylamino- C_{2-7} alkoxy, (N-C₁₋₈-alkyl)-C₁₋₈-alkylcarbonylamino-C₁₋₈-alkyl, (N-C₁₋₈-alkyl)-C₁₋₈alkylcarbonylamino-C2-ralkoxy, C3-6-cycloalkylcarbonylamino-C1-6-alkyl, C2-6cycloalkylcarbonylamino-C₂₋₇-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, hydroxy- $C_{2,7}$ -alkoxy- $C_{1,6}$ -alkyl, hydroxy- $C_{2,7}$ -alkoxy- $C_{1,6}$ -alkoxy, $C_{1,6}$ -alkoxy-carbonylamino- $C_{1,6}$ alkyl, $C_{1,s}$ -alkoxycarbonylamino- $C_{2,r}$ -alkoxy, $C_{1,s}$ -alkylaminocarbonylamino- $C_{1,s}$ -alkyl C1-a-alkylaminocarbonylamino-C2-alkoxy, C1-alkylaminocarbonyl-C1-alkyl, C1-alkyl alkylaminocarbonyl- $C_{1.6}$ -alkoxy, $C_{1.6}$ -alkylaminocarbonyl- $C_{1.6}$ -alkoxy- $C_{1.6}$ -alkyl, di- $C_{1.6}$ alkylaminocarbonyl-C_{1.6}-alkyl, di-C_{1.6}-alkylaminocarbonyl-C_{1.6}-alkoxy, C_{1.6}alkylcarbonyloxy-C_{1.6}-alkyl, C_{1.6}-alkylcarbonyloxy-C_{2.6}-alkoxy, cyano-C_{1.6}-alkyl, cyano- C_{1-6} -alkoxy, 2-oxooxazolidinyl- C_{1-6} -alkyl, 2-oxo-oxazolidinyl- C_{1-6} -alkoxy, C_{1-6} alkoxycarbonyl-C1-6-alkyl, C1-6-alkoxycarbonyl-C1-6-alkoxy, C1-6-alkylsulphonylamino-C1--alkyl. C1.-alkylsulphonylamino-C2-alkoxy, (N-C1.-alkyl)-C1.-alkylsulphonylamino-C1. ₈-alkyl, (N-C₁₋₆-alkyl)-C₁₋₈-alkylsulphonylamino-C₂₋₇-alkoxy, C₁₋₈-alkylamino-C₁₋₈-alkyl, C_{1-8} -alkylamino- C_{2-7} -alkoxy, di- C_{1-8} -alkylamino- C_{1-8} -alkylamino- C_{2-7} -alkoxy. C1-e-alkylsulphonyl-C1-e-alkyl, C1-e-alkylsulphonyl-C1-e-alkoxy, carboxy-C1-e-alkyl, carboxy-C₁₋₆-alkoxy, carboxy-C₁₋₈-alkoxy-C₁₋₈-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkylcarbonyl, acyl- C_{1-6} -alkexy- C_{1-6} -alkyl, (N- C_{1-6} -alkyl)- C_{1-6} -alkoxycarbonylamine, (N-hydroxy)- C_{1-6} alkylaminocarbonyl-C_{1-s}-alkyl, (N-hydroxy)-C_{1-s}-alkylaminocarbonyl-C_{1-s}-alkoxy, (Nhydroxy)aminocarbonyl-C₁₋₆-alkyl, (N-hydroxy)aminocarbonyl-C₁₋₆-alkoxy, C₁₋₆-alkoxyaminocarbonyl-C₁₋₈-alkyl, 6-alkoxyaminocarbonyl-C₁₋₉-alkoxy, (N-C₁₋₆-alkoxy)-C₁₋₉alkylaminocarbonyl-C₁₋₈-alkyl, (N-C₁₋₈-alkoxy)-C₁₋₈-alkylaminocarbonyl-C₁₋₈-alkoxy, (N-C₁₋₈-alkoxy) acyl)-C₁₋₆-alkoxy-C₁₋₆-alkylamino, C₁₋₆-alkoxy-C₁₋₆-alkylcarbamoyl, (N-C₁₋₆-alkyl)-C₁₋₆-

alkoxy- C_{1-6} -alkylcarbamoyl, C_{1-6} -alkoxy- C_{1-6} -alkylcarbonyl, C_{1-6} -alkoxy- C_{1-6} - C_{1-6} -Calkylcarbonylamino, (N-C₁₋₅-alkyl)-C₁₋₆-alkoxy-C₁₋₆-alkylcarbonylamino, 1-C₁₋₆-alkoxy- C_{1-8} -alkylimidazol-2-yi, 1- C_{1-8} -alkoxy- C_{1-8} -alkyltetrazol-5-yi, 5- C_{1-8} -alkoxy- C_{1-8} -alkoxy- C_{1-8} -alkyltetrazol-5-yii, 5- C_{1-8} -alkoxy- C_{1-8} -alkyltetrazol-5-yii, 5- C_{1-8} alkyltetrazol-1-yl, 2-C₁₋₅-alkoxy-C₁₋₅-alkyl-4-oxolmidazol-1-yl, carbamoyl-C₁₋₆-alkyl, carbamoyl- C_{1-8} -alkoxy, C_{1-8} -alkylcarbamoyl, di- C_{1-8} -alkylcarbamoyl, C_{1-8} -alkylsulphonyl, C_{1-8} -alkylamidinyl, acetamidinyl- C_{1-8} -alkyl, O-methyloximyl- C_{1-8} -alkyl, O,Ndimethylhydroxylamine- C_{1-8} -alkyl, C_{3-8} -cycloalkyl- C_{1-8} -alkanoyl, aryl- C_{1-6} -alkanoyl or heterocyclyl-C₁₋₆-alkanoyl, or else pyridyl, pyridyloxy, pyridylthio, pyridylamino, pyridyl- C_{1-e} -alkyl, pyrldyl- C_{1-e} -alkoxy, pyrimidinyl, pyrimidinyloxy, pyrimidinylthio, pyrimidinylamino, pyrimidinyl- $C_{1.8}$ -alkyl, pyrimidinyl- $C_{1.8}$ -alkoxy, thienyl, thienyl- $C_{1.8}$ alkyl. thienyl-C1.5 alkoxy, furyl, furyl-C1.5 alkyl or furyl-C1.5 alkoxy, each of which is optionally substituted by halogen, C_{1.5}-alkyl, C_{1.5}-alkoxy or dihydroxy-C_{1.5}alkylaminocarbonyl, piperidinoalkyl, piperidinoalkoxy, piperidinoalkoxyalkyl, morpholinoalkyt, morpholinoalkoxy, morpholinoalkoxyalkyt, piperazinoalkyt, piperazinoalkoxy, piperazinoalkoxyalkyl, [1.2,4]-triazol-1-ylalkyl, [1,2,4]-triazol-1ylalkoxy, [1,2,4]-triazol-4-ylalkyi, [1,2,4]-triazol-4-ylalkoxy, [1,2,4]-oxadiazol-5-ylalkyi, [1.2,4]-oxadiazol-S-ylalkoxy, 3-methyl-[1,2,4]-oxadiazol-S-ylalkyl, 3-methyl-[1,2,4]oxadlazol-5-ylalkoxy, 5-methyl-[1,2,4]-oxadlazol-3-ylalkyl, 5-methyl-[1,2,4]-oxadlazol-3ylalkoxy, tetrazol-1-ylalkyt, tetrazol-1-ylalkoxy, tetrazol-2-ylalkyt, tetrazol-2-ylalkoxy, tetrazol-5-ylalkyl, tetrazol-5-ylalkoxy, 5-methyl-tetrazol-1-ylalkyl, 5-methyl-tetrazol-1ylalkoxy, thiazol-4-ylalkyl, thiazol-4-ylalkoxy, oxazol-4-ylalkyl, oxazol-4-ylalkoxy, 2-oxopyrrolidinyfalkyl, 2-oxo-pyrrolidinylalkoxy, imidazolylalkyl, imidazolylalkoxy, 2-methylimidazolylalkył, 2-methyl-imidazolylalkoxy, N-methylpiperazinoalkył, Nmethylpiperazinoalkoxy, N-methylpiperazinoalkoxyalkyl, dioxolanyl, dioxanyl, dithiolanyl, dithianyl, pyrrolldinyl, piperidinyl, piperazinyl, pyrrolyl, 4-methylpiperazinyl, morpholinyl, thiomorpholinyl, 2-hydroxymethylpyrrolidinyl, 3-hydroxypyrrolidinyl, 3,4dihydroxypyrrolidinyl, 3-acetamidomethylpyrrolidinyl, 3-C, -alkoxy-C, -alkylpymolidinyl, 4-hydroxypipendinyl, 4-oxopipendinyl, 3,5-dimethylmorpholinyl, 4,4dioxothiomorpholinyl, 4-oxothiomorpholinyl, 2,6-dimethylmorpholinyl, 2-oxoimidazolidinyi. 2-oxooxazolidinyi, 2-oxopyrrolidinyi, 2-oxo-[1,3]oxazinyi, 2-oxotetrahydropyrimidinyl and the -O-CH2CH(OH)CH2NR, radical where NR, is a mono- or di-C1-6-alkylamino, piperidino, morpholino, piperazino or N-methylpiperazino radical;

or a prodrug thereof, which on *in vivo* application, release a compound of formula (1) by a chemical or physiological process, or in which one or more atoms have been replaced by their stable, non-radioactive isotopes, or a salt thereof.

8. (Cancelled)

- 9. (Previously presented) A pharmaceutical preparation comprising, as an active pharmaceutical ingredient, a compound according to Claim 1 or 7 in free form or as a pharmaceutically usable salt.
- 10. (Previously presented) A process for preparing a medicament for the treatment of hypertension, heart failure, glaucoma, myocardial infarction, kidney failure or restenses, which comprises blending a compound according to Claim 1 or 7 with a pharmaceutically inert, inorganic or organic excipient.
- 11. (Previously presented) A process according to Claim 10, characterized in that the preparation is effected additionally with one or more agents having cardiovascular action, for example α- and β-blockers such as phentolamine, phenoxybenzamine, prazosin, terazosin, tolazine, atenolol, metoprolol, nadolol, propranolol, timolol, carteolol etc.; vasodilators such as hydralazine, minoxidil, diazoxide, nitroprusside, flosequinan etc.; calcium antagonists such as amrinone, bencyclan, diltiazem, fendiline, flunarizine, nicardipine, nimodipine, perhexilene, verapamil, gallopamil, nifedipine etc.; ACE inhibitors such as cilazapril, captopril, enalapril, lisinopril etc.; potassium activators such as pinacidil; anti-serotoninergics such as ketanserin; thromboxane-synthetase inhibitors; neutral endopeptidase inhibitors (NEP inhibitors); angiotensin II antagonists; and also diuretics such as hydrochlorothiazide, chlorothiazide, acetazolamide, amiloride, bumetanide, benzthiazide, ethacrynic acid, furosemide, indacrinone, metolazone, spironolactone, triamteren, chlorthalidone etc.; sympatholytics such as methyldopa, clonidine, guanabenz, reserpine; and other agents which are suitable for the treatment of

hypertension, heart failure or vascular diseases in humans and animals which are associated with diabetes or renal disorders such as acute or chronic renal failure.

12. (Previously presented) A method for the treatment of hypertension, heart failure, myocardial infarction, kidney failure or restenses, characterized in that the human or animal body is treated with an effective amount of a compound according to Claim 1 or 7.